Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025.
Petros Grivas, MD, PhD
Advertisement
Articles by Petros Grivas, MD, PhD
Petros Grivas, MD, PhD, highlights notable trial readouts across NMIBC, MIBC, and urothelial carcinoma.
Frontline treatment approaches recommended by urologists and medical oncologists for patients with non-metastatic muscle-invasive bladder cancer.
Administration of systemic therapy and management of side effects in patients with bladder cancer.
Advertisement
Latest Updated Articles
Petros Grivas, MD, on the significance of a perioperative regimen for cisplatin-ineligible MIBCPublished: October 31st 2025 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
